Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 3/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.60 |
| ▸ | APP | P05067 | 7/20 | 0.60 |
| ▸ | MAOB | P27338 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30730012 | 1.00 | BACE1 (0.60) | BACE1PTPN1APPMAOBKMT2A | |
| SCHEMBL27414810 | 1.00 | BACE1 (0.60) | BACE1PTPN1APPMAOBKMT2A | |
| SCHEMBL27160315 | 1.00 | BACE1 (0.60) | BACE1PTPN1APPMAOBKMT2A | |
| SCHEMBL27414819 | 0.93 | BACE1 (0.60) | BACE1PTPN1APPMAOBKMT2A | |
| SCHEMBL15970480 | 0.90 | BACE1 (0.60) | BACE1PTPN1APPMAOBKMT2A | |
| SCHEMBL14248288 | 0.90 | BACE1 (0.60) | BACE1PTPN1APPMAOBKMT2A | |
| SCHEMBL12539779 | 0.89 | BACE1 (0.56) | BACE1PTPN1APPMAOBKMT2A | |
| SCHEMBL15970523 | 0.89 | APP (0.62) | BACE1PTPN1APPMAOBKMT2A | |
| SCHEMBL14248951 | 0.89 | APP (0.62) | BACE1PTPN1APPMAOBKMT2A | |
| SCHEMBL23888029 | 0.87 | APP (0.47) | BACE1PTPN1APPMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-53149979-A | — | — | None | — | — | JP | disclosed |
| EP-2344142-B1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS INC (US) | 2024-06-26 | — | — | EP | disclosed |
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9399612-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-9399612-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2016-07-26 | — | — | US | disclosed |
| US-20150239818-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150239818-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2015-08-27 | — | — | US | disclosed |
| US-8969420-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969420-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2015-03-03 | — | — | US | disclosed |
| US-20140206772-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2014-07-24 | — | — | US | disclosed |
| US-8653144-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653144-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | EDISON PHARMACEUTICALS, INC. (US) | 2013-02-28 | — | — | US | disclosed |
| US-8314153-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314153-B2 | Treatment of pervasive developmental disorders with redox-active therapeutics | EDISON PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | PTC THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
| JP-S53149979-A | PREPARATION OF ALPHA-TOCOTRIENOL NICOTINIC ACID ESTER | TAKASAGO CORP | 1978-12-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170157065-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | BACE1 132/4885PTPN1 2118/4885APP 305/4885 |
| US-20140206772-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, DDT, ADH4 | BACE1 132/4885PTPN1 2108/4885APP 304/4885 |
| US-20130053450-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | BACE1 132/4885PTPN1 2118/4885APP 305/4885 |
| US-20150239818-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | BACE1 132/4885PTPN1 2118/4885APP 305/4885 |
| US-20100063161-A1 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS | COMT, ADH4, DDT | BACE1 132/4885PTPN1 2118/4885APP 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.